The unblinding of phase 3 trial data of SynCore Biotechnology Co Ltd’s (杏國新藥) newly developed pancreatic cancer drug SB05PC showed no statistical significance when compared with the control group, the drugmaker said yesterday.
SB05PC is designed to prolong patients’ lives, and the trial ended once all participants had passed away, the company said.
The trials tested whether people taking the drug would on average live significantly longer than those in the control group, it added.
Photo: CNA
The trials tested for overall survival time — the time the patient survives from the beginning of treatment — and progression-free survival time — the time the patient’s cancer does not worsen from the beginning of treatment, it said.
The median overall survival time for the 108 participants treated with SB05PC was 226 days, while their median progression-free survival time was 113 days.
Meanwhile, the median overall survival time of the 100 patients in the control group was 209 days, while their median progression-free survival time was 110 days, the drugmaker said.
“The difference between the two groups was not statistically significant,” Tim Lee (李志文), chairman of the drugmaker’s parent company Sinphar Pharmaceutical Co Ltd (杏輝醫藥), told a news conference in Taipei.
Other secondary gauges, such as disease control rate, objective response, rate and duration of response also did not show statistical significance, the company said.
The disease control rate averaged 59.38 percent in the treatment group, compared with 48.86 percent in the control group; the objective response rate was 11.46 percent in the treatment group, compared with 6.82 percent in the control group; and response to the drug averaged 4.1 months in the treatment group, compared with 5.6 months in the control group, it said.
SB05PC was developed as a second-line treatment to be combined with chemotherapy drug gemcitabine for patients who do not respond well to first-line drug Folfirinox, SynCore said.
Trail participants either received SB05PC in combination with gemcitabine, or only gemcitabine in the control group, it said.
Although no statistical significance, which would allow SynCore to seek approval for the treatment, was found, the trials were meaningful, as it would base the further development of SB05PC on the results, Lee said.
Phase 3 trials were conducted in seven countries — Taiwan, the US, France, Hungary, Israel, Russia and South Korea — and some populations seemed to react better to the drug, Lee said.
“It was a valuable experience, and we also learned how to be more exact in deciding the development direction of a new drug. This experience is an intangible asset,” Lee said.
SynCore has been developing SB05PC for six years, investing NT$2 billion (US$71.65 million) in the treatment, Lee said, adding that Sinphar funded the project with NT$1.77 billion.
After ending the project, Sinphar is expected to regain profitability, Lee said, aiming to post annual net profit of about NT$400 million.
SynCore reported a net loss of NT$159 million for the first six months of this year, while Sinphar reported net profit of NT$10.34 million, down 71 percent from a year earlier, Sinphar data showed.
JITTERS: Nexperia has a 20 percent market share for chips powering simpler features such as window controls, and changing supply chains could take years European carmakers are looking into ways to scratch components made with parts from China, spooked by deepening geopolitical spats playing out through chipmaker Nexperia BV and Beijing’s export controls on rare earths. To protect operations from trade ructions, several automakers are pushing major suppliers to find permanent alternatives to Chinese semiconductors, people familiar with the matter said. The industry is considering broader changes to its supply chain to adapt to shifting geopolitics, Europe’s main suppliers lobby CLEPA head Matthias Zink said. “We had some indications already — questions like: ‘How can you supply me without this dependency on China?’” Zink, who also
At least US$50 million for the freedom of an Emirati sheikh: That is the king’s ransom paid two weeks ago to militants linked to al-Qaeda who are pushing to topple the Malian government and impose Islamic law. Alongside a crippling fuel blockade, the Group for the Support of Islam and Muslims (JNIM) has made kidnapping wealthy foreigners for a ransom a pillar of its strategy of “economic jihad.” Its goal: Oust the junta, which has struggled to contain Mali’s decade-long insurgency since taking power following back-to-back coups in 2020 and 2021, by scaring away investors and paralyzing the west African country’s economy.
BUST FEARS: While a KMT legislator asked if an AI bubble could affect Taiwan, the DGBAS minister said the sector appears on track to continue growing The local property market has cooled down moderately following a series of credit control measures designed to contain speculation, the central bank said yesterday, while remaining tight-lipped about potential rule relaxations. Lawmakers in a meeting of the legislature’s Finance Committee voiced concerns to central bank officials that the credit control measures have adversely affected the government’s tax income and small and medium-sized property developers, with limited positive effects. Housing prices have been climbing since 2016, even when the central bank imposed its first set of control measures in 2020, Chinese Nationalist Party (KMT) Legislator Lo Ting-wei (羅廷瑋) said. “Since the second half of
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) received about NT$147 billion (US$4.71 billion) in subsidies from the US, Japanese, German and Chinese governments over the past two years for its global expansion. Financial data compiled by the world’s largest contract chipmaker showed the company secured NT$4.77 billion in subsidies from the governments in the third quarter, bringing the total for the first three quarters of the year to about NT$71.9 billion. Along with the NT$75.16 billion in financial aid TSMC received last year, the chipmaker obtained NT$147 billion in subsidies in almost two years, the data showed. The subsidies received by its subsidiaries —
RSS